SCHEMBL5537153

SCHEMBL5537153

CNC1CCN(c2ccc(O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME3 Q16798 3/20 0.52
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
PKM P14618 1/20 0.49
TDP1 Q9NUW8 1/20 0.47
MCHR1 Q99705 1/20 0.42
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41
USP2 O75604 1/20 0.41
DRD4 P21917 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL3 Q96JM7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ME2 P23368 1/20 0.40
ME1 P48163 1/20 0.40
DEGS1 O15121 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31142768 0.98 ME3 (0.51) ME3KDM4EMAPTALDH1A1PKM
SCHEMBL8728954 0.83 ADRB1 (0.50) KDM4EMAPTALDH1A1MCHR1GAA
SCHEMBL3440289 0.83 MAPT (0.55) KDM4EMAPTALDH1A1TDP1MCHR1
SCHEMBL5537144 0.81 MCHR1 (0.42) ME3KDM4EMAPTALDH1A1MCHR1
SCHEMBL21590255 0.81 NPY5R (0.46) MCHR1USP2KMT2AL3MBTL3L3MBTL1
SCHEMBL8728952 0.81 L3MBTL3 (0.40) ME3KDM4EMAPTALDH1A1MCHR1
SCHEMBL785834 0.81 KMT2A (0.50) KDM4EMAPTGAADRD4MEN1
SCHEMBL22837853 0.81 LTA4H (0.41) ME3KDM4EMAPTALDH1A1MCHR1
SCHEMBL784590 0.81 MAPT (0.53) KDM4EMAPTALDH1A1TDP1LMNA
SCHEMBL7049802 0.81 L3MBTL1 (0.52) ME3KDM4EALDH1A1MCHR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ME3 146/4885KDM4E 4854/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.